Recommended on Univadis

  • Univadis
  • 1 comment

ASCO 2017 - Metastatic castration-resistant prostate cancer: indoximod after sipuleucel-T boosts PFSl in phase 2 trial

New role for an IDO pathway inhibitor.

Read more
  • Univadis
  • 1 comment

ASCO 2017 - Relapsed/refractory diffuse large B-cell lymphoma: JCAR017 achieves high CR rates in phase 1 trial

Read more
  • Univadis
  • no comment

ASCO 2017 - Relapsed/refractory multiple myeloma: LCAR-B38M yields 100% ORR in phase 1 trial

Read more
  • Univadis
  • 1 comment

ASCO 2017 - Melanoma brain mets: nivolumab+ipilimumab deliver promising phase 2 results

Read more
  • Univadis
  • no comment

ASCO 2017 - NHL: 82% ORR with axicabtagene ciloleucel in phase 1/2 ZUMA-1 trial

Read more
  • Univadis
  • 1 comment

ASCO 2017 - High-risk breast cancer: pembrolizumab+standard therapy improved pathologic complete response rates

Read more
  • Univadis
  • 1 comment

ASCO 2017 - Advanced SCLC: promising results with nivolumab±ipilimumab

Read more
  • Univadis
  • 1 comment

ASCO 2017 - Precursor B-cell ALL: 95% CR with autologous T cells genetically targeted to B-cell-specific antigen CD19

Read more
  • Univadis
  • 1 comment

ASCO 2017 - NSCLC: phase 3 study suggests prolonged survival benefit with atezolizumab

Read more

Professional Essentials

  • Patients Will Be Asking

Is Zika still a threat?

Read more
  • US Professional News

PCPs: fickle millennials may move on

Read more
  • US Professional News

Senate health bill includes cuts to Medicaid

Read more
  • US Professional News

AMA campaign aimed at easy MIPS compliance

Read more
  • US Professional News

MACRA reporting eased in proposal

Read more
  • Patients Will Be Asking

Can I get a "gentle" cesarean?

Read more
View more

New on Univadis

  • Clinical Essentials from Leukemia
  • 1 comment

Phase 3 results for darbepoetin alfa in lower-risk MDS with anemia

Meaningful effect on rates of transfusion and erythroid response.

Read more
  • Clinical Essentials from Eur Urol
  • 1 comment

Urological cancers: where do checkpoint inhibitors fit in the treatment paradigm?

Systematic review involves pembrolizumab, nivolumab, and ipilimumab in advanced urothelial, renal, and prostate cancer.

Read more
  • Clinical Essentials from Ann Surg
  • 1 comment

HCC: higher recurrence risk with male liver donors

Association decreases with age.

Read more
  • Clinical Essentials from Aliment Pharmacol Ther
  • no comment

DAAs for HCV: no evidence of HBV reactivation with resolved infection

Data from a large, real-world cohort.

Read more
  • Clinical Essentials from Contraception
  • 1 comment

First trimester surgical abortion: nitrous oxide equal to oral sedation for pain

Nitrous oxide carries the benefit of having no aftereffects, thus not requiring a ride home.

Read more
  • Clinical Essentials from Int J Rheum Dis
  • 1 comment

Anti-CCP antibodies in RA predict carotid plaque

And higher titers predict worse plaque score.

Read more
  • Clinical Essentials from J Stroke Cerebrovasc Dis
  • 1 comment

IVT for stroke: nonintracranial hemorrhage common, but outcomes unaffected

NICH is a common IVT complication, but effects on outcomes were poorly understood.

Read more
  • Clinical Essentials from Diabetes Care
  • 1 comment

OGTT best predicts CAD risk in patients with dysglycemia

A report from EUROASPIRE IV.

Read more
  • Clinical Essentials from Circulation
  • 1 comment

Lower BP targets may yield CV benefits in high-risk patients

Study involving over 31K patients supports BP target below 140/90 mmHg,

Read more
  • Clinical Essentials from JAMA Oncol
  • 1 comment

PPI+capecitabine: worse outcomes in gastroesophageal cancer

Similar to previous findings in CRC.

Read more
  • Clinical Essentials from N Engl J Med
  • 1 comment

Recombinant influenza vaccine offers better protection for seniors

Study of 9003 patients aged 50 and older shows 30% greater efficacy vs inactivated vaccine.

Read more
  • Clinical Essentials from Cochrane Database Syst Rev
  • no comment

Cochrane review: umeclidinium in COPD

A systematic summary of the effectiveness and safety of umeclidinium in COPD.

Read more
  • Clinical Essentials
  • 1 comment

Pediatric celiac disease: new guidelines and web tool for diagnosis

From the Celiac Disease Foundation.

Read more
  • Clinical Essentials from Breast
  • 1 comment

Metastatic breast cancer: CDK4/6 inhibitors are well-tolerated

Results of a meta-analysis of palbociclib and ribociclib.

Read more